| Companies Involved | AIO Studien gGmbH, Amgen, ARCAGY/GINECO Group, AstraZeneca, Azienda Ospedaliera Universitaria Senese, Canadian Cancer Trials Group, Charite - Universitatsmedizin Berlin, Dana-Farber Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Grupo Espanol de Tumores Neuroendocrinos, Hoosier Cancer Research Network, Immunocore, Institute Gustave-Roussy, Kyoto Breast Cancer Research Network, M. D. Anderson Cancer Center, MedImmune, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), Northwestern University, Pfizer, Seoul National University Hospital, UNICANCER, University College London, University of Maryland Greenbaum Cancer Center, Yonsei University College of Medicine |
| Conditions Active | Head and neck cancer, Liver cancer, Mesothelioma, Non-small cell lung cancer, Renal cell carcinoma, Small cell lung cancer, Solid tumours, Urogenital cancer, Biliary cancer, Bladder cancer, Breast cancer, Cholangiocarcinoma, Colorectal cancer, Endometrial cancer, Fallopian tube cancer, Gallbladder cancer, Gastric cancer, Gastrointestinal cancer, Germ cell and embryonal neoplasms, Glioblastoma, Lung cancer, Neuroendocrine tumours, Oropharyngeal cancer, Ovarian cancer, Pancreatic cancer, Peritoneal cancer, Prostate cancer, Sarcoma, Soft tissue sarcoma, Thyroid cancer, Haematological malignancies, Malignant melanoma, Oesophageal cancer, Cervical cancer, Diffuse large B cell lymphoma, Gynaecological cancer, Myelodysplastic syndromes, Vulvovaginal cancer |
